Kaplan-Meier curves showing overall survival (A) and progression free survival (B) with 95% confidence intervals (CI) in the patients enrolled.

<p>Kaplan-Meier curves showing overall survival (A) and progression free survival (B) with 95% confidence intervals (CI) in the patients enrolled.</p

A schematic diagram of the current phase II study design.

<p>A schematic diagram of the current phase II study design.</p

Toxicities observed in the treated patients (n = 25).

<p>Toxicities observed in the treated patients (n = 25).</p

Baseline clinical and demographic characteristics of enrolled patients (n = 26).

<p>Baseline clinical and demographic characteristics of enrolled patients (n = 26).</p

Tumor responses to the FOLFOX regimen in patients of differing <i>TSER</i> genotypes.

<p>PD, progressive disease; PR, partial response; SD, stable disease.</p>a<p>Calculated using Fisher’s exact test for the association between response (PR and SD) and <i>TSER</i> genotype.</p><p>Tumor responses to the FOLFOX regimen in patients of differing <i>TSER</i> genotypes.</p

Kaplan-Meier curves showing overall survival (A) and progression free survival (B) according to <i>TSER</i> genotypes.

<p>Kaplan-Meier curves showing overall survival (A) and progression free survival (B) according to <i>TSER</i> genotypes.</p